Results 131 to 140 of about 13,549 (163)
Comment on "how the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes". [PDF]
OncologistRichter J, Davis M, Chai Y.
europepmc +1 more source
Enhancing oncolytic reovirus therapy with proteasome inhibitors in multiple myeloma. [PDF]
Ann Med Surg (Lond)Aleem MR, Baloch K, Shahid M, Talha SS.
europepmc +1 more source
Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents. [PDF]
World J MethodolAlam F +14 more
europepmc +1 more source
Multiple myeloma: an overview of drug therapies and supportive care. [PDF]
Aust PrescrHocking J.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Blood, 2013
Abstract This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have ...
Keith Stewart, K Martin Kortuem
exaly +4 more sources
Abstract This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have ...
Keith Stewart, K Martin Kortuem
exaly +4 more sources
The Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma
Therapeutic Advances in Hematology, 2021 Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone ...
Andrew J Yee
exaly +2 more sources
Reactions Weekly, 2018
Carfilzomib (CFZ) is a potent, second-generation proteasome inhibitor (PI), with significant activity as a single agent and in combination with other antimyeloma agents in patients with relapsed or refractory multiple myeloma (RRMM). CFZ binds selectively and irreversibly to its target and leads to antiproliferative and proapoptotic effects on cancer ...
Engelhardt, Monika +6 more
+6 more sources
Carfilzomib (CFZ) is a potent, second-generation proteasome inhibitor (PI), with significant activity as a single agent and in combination with other antimyeloma agents in patients with relapsed or refractory multiple myeloma (RRMM). CFZ binds selectively and irreversibly to its target and leads to antiproliferative and proapoptotic effects on cancer ...
Engelhardt, Monika +6 more
+6 more sources
Carfilzomib: A Novel Second-Generation Proteasome Inhibitor
Future Oncology, 2011 Carfilzomib (formerly PR-171) is a novel epoxyketone-based irreversible proteasome inhibitor. In preclinical studies, carfilzomib demonstrated irreversible binding to the proteasome and minimal off-target inhibition of other proteases.
A Keith Stewart, Meaghan L Khan
exaly +2 more sources